{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-007712","form_type":"8-K","ticker":"VSTM","cik":"0001526119","company_name":"Verastem, Inc.","filed_at":"2024-01-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.492628+00:00","generated_at":"2026-06-06T15:54:01.670652+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Verastem outlines 2024 priorities: NDA submission for avutometinib/defactinib in LGSOC in H1 2024","bullets":["Plans to begin rolling NDA submission for accelerated approval of avutometinib/defactinib in recurrent LGSOC in H1 2024; potential commercial launch in 2025.","Initial data from RAMP 205 trial of avutometinib/defactinib plus chemo in frontline metastatic pancreatic cancer expected H1 2024.","Data from RAMP 203 and RAMP 204 trials in KRAS G12C-mutant NSCLC planned for mid-2024.","Interim RAMP 201 results showed ORR 45% (13/29) and disease control 86% (25/29) in LGSOC; Phase 3 RAMP 301 initiated.","Collaborator GenFleet to advance oral KRAS G12D inhibitor GFH375/VS-7375 into Phase 1 in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-007712","json":"https://secwatch.observer/filing/0001104659-24-007712.json","markdown":"https://secwatch.observer/filing/0001104659-24-007712.md","text":"https://secwatch.observer/filing/0001104659-24-007712.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1526119/000110465924007712/0001104659-24-007712-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1526119/000110465924007712/tm244111d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T15:54:01.670652+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}